Application of ppMAKL as target spot in screening medicine for treating solid tumor liver metastasis

By discovering circular RNA circMASTL-M and its encoded ppMAKL, screening small molecule compound K279-0671, the problem of lack of effective therapeutic targets for liver metastasis in breast cancer was solved, effective inhibition of liver metastasis was achieved, and therapeutic effect was improved. Survival prognosis.

CN118910255APending Publication Date: 2024-11-08ZHEJIANG CANCER HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410963734.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The lack of effective therapeutic targets for liver metastasis in breast cancer, which makes the treatment refractory. The existing technology has failed to effectively solve the problems of molecular mechanisms and targeted drug development of liver metastasis.

Method used

By discovering that circular RNA circMASTL-M is specifically highly expressed in liver metastasized tissues, encoding a novel kinase-like polypeptide ppMAKL, the small molecule compound K279-0671 is screened using computer simulation and molecular docking technology to inhibit ppMAKL activity, thereby developing targeted drugs to Inhibit liver metastasis.

Benefits of technology

Small molecule compound K279-0671 significantly inhibits the progress of liver metastasis in clinically common solid tumor models, improves the treatment effect and survival prognosis, and has good clinical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910255A_ABST
    Figure CN118910255A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to application of ppMAKL as a target spot to screening of drugs for treating solid tumor liver metastasis. The ppMAKL provided by the invention can be used as a target spot to effectively screen drugs for treating solid tumor liver metastasis. According to the invention, a small molecular compound K279-0671 is obtained by screening through computer simulation and molecular docking technologies; k279-0671 single drugs with different concentrations are used for treating the constructed solid tumor liver metastasis animal model, the intraperitoneal injection concentrations of 25 mg / kg and 50 mg / kg are adopted, the liver metastasis progress can be well inhibited, and diseases are relieved on the 20th day; a single drug K279-0671 is constructed to treat a patient-derived liver metastatic tumor organ model and a liver metastatic tumor xenotransplantation tumor model, and the K279-0671 can well inhibit the growth of liver metastatic tumor organs and the growth of transplantation tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the application of ppMAKL as a target in screening drugs for treating liver metastasis of solid tumors. Background Art

[0003] The reticular anatomical structure of the liver is conducive to the retention of tumor cells; the liver is an organ with rich blood flow, which provides sufficient nutrition for the growth of tumor cells. Other components in the liver microenvironment promote the growth of tumor cells by interacting with tumor cells or by secreting cytokines and inflammatory factors. The liver is a common organ for solid tumor metastasis. Compared with metastasis to other extracranial internal organs, patients with liver metastasis have the worst survival prognosis. For breast cancer, the liver is also one of its common metastatic sites. In autopsies, about 71% of breast cancer cases were found to have liver metastasis to varying degrees. The occurrence of liver metastasis will further reduce the 5-year survival rate of breast cancer to about 8.5%, and the median survival time is only 3-15 months. At the same time, there is a lack of effective therapeutic targets for liver metastasis of breast cancer, and most patients are prone to multiple drug resistance during treatment, leading to treatment failure, or treatment is discontinued due to inability to tolerate the toxic and side effects of systemic chemotherapy, which is an important reason for its refractory nature. Therefore, elucidating the molecular mechanism of breast cancer liver metastasis and screening and identifying effective biological targets are of great clinical significance for developing new targeted drugs to improve the therapeutic effect and survival prognosis of liver metastasis.

[0004] Circular RNA (circRNA) is a type of non-coding RNA that is formed by reverse editing of linear RNA and does not have a 5'-cap and 3'-polyA tail. The expression of circRNA is often tissue-specific and spatiotemporal-specific, and the forms of interaction with target genes are diverse. It can act as a microRNA "sponge" to regulate the expression of target genes, or as a signal molecule, scaffold, bait or guide to regulate the subcellular localization, post-translational modification, stability and other functions of target genes, thereby playing an important role in the biological behaviors of tumor cell growth, differentiation, invasion, etc. In recent years, more and more studies have focused on the potential of circRNA to encode new polypeptides, expanding the biological functions of circRNA from a new dimension. For example, circAKT3 encodes a novel polypeptide AKT3-174aa, which competitively binds to phosphorylated PDK1 and inhibits the phosphorylation of AKT, thereby inhibiting the malignant proliferation of brain glioma cells; in hepatocellular carcinoma, circβ-catenine encodes a 370aa β-catenine isomer, which blocks the phosphorylation and degradation of β-catenine by GSK3β, leading to abnormal activation of the Wnt signaling pathway and promoting the proliferation of hepatocellular carcinoma. However, so far, no studies have found the regulatory relationship between the polypeptide encoded by the circMASTL-M gene and the occurrence and development of tumors. Summary of the invention

[0005] The purpose of the present invention is to provide an application of ppMAKL as a target in screening drugs for treating liver metastasis of solid tumors, so as to solve the problems existing in the above-mentioned prior art. The ppMAKL of the present invention can be used as a target to effectively screen drugs for treating liver metastasis of solid tumors, and substances that inhibit the activity of ppMAKL can be used as drugs for treating liver metastasis of solid tumors.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] The present invention provides the use of ppMAKL as a target in screening drugs for treating liver metastasis of solid tumors, wherein the amino acid sequence of the ppMAKL is shown in SEQ ID NO.5.

[0008] Preferably, the solid tumors include breast cancer, colorectal cancer and non-small cell lung cancer.

[0009] The present invention provides use of a preparation for inhibiting the activity of ppMAKL in preparing a drug for treating liver metastasis of solid tumors, wherein the amino acid sequence of the ppMAKL is shown in SEQ ID NO.5.

[0010] Preferably, the drug achieves the treatment of solid tumor liver metastasis by increasing oxidative stress-induced ferroptosis of metastatic tumor cells and inhibiting the formation of liver metastasis.

[0011] Preferably, the solid tumors include breast cancer, colorectal cancer and non-small cell lung cancer.

[0012] The present invention provides an application of a small molecule compound K279-0671 in the preparation of a drug for treating liver metastasis of solid tumors. The chemical structural formula of the small molecule compound K279-0671 is shown in Formula I.

[0013]

[0014] Preferably, the drug achieves the treatment of solid tumor liver metastasis by inhibiting the metastasis of cancer cells to the liver.

[0015] The present invention provides a drug for treating liver metastasis of solid tumors. The active ingredient of the drug includes a small molecule compound K279-0671. The chemical structure of the small molecule compound K279-0671 is shown in Formula I.

[0016]

[0017] Preferably, the drug further comprises pharmaceutically acceptable excipients.

[0018] Preferably, the dosage form of the drug is injection, granules, powder or capsule.

[0019] The present invention discloses the following technical effects:

[0020] The experiments of the present invention found that the circular RNA, circMASTL-M, was specifically and highly expressed in solid tumor liver metastasis tissues and tumor cells with stable liver metastasis. After overexpression of circMASTL-M in tumor cells without metastasis, the resistance of tumor cells to oxidative stress was significantly increased, which was manifested as a decrease in lipid peroxidation levels and a decrease in tumor cell death. Mechanistic studies found that circMASTL-M encoded a new kinase-like polypeptide, ppMAKL, which enhanced the metabolic pathway for the production of reducing substances such as NADPH and glutathione in tumor cells, thereby resisting cell death caused by oxidative stress during the metastasis process, thereby promoting the occurrence of solid tumor liver metastasis. Targeting the kinase-like active cavity of ppMAKL, a small molecule compound K279-0671 with affinity for the active cavity was screened from a library of 14 compounds through computer simulation and molecular docking technology; by constructing an animal model of liver metastasis of solid tumors, including common liver metastases in clinical practice such as breast cancer, colorectal cancer and non-small cell lung cancer, a single-agent treatment experiment was carried out with different concentrations of the small molecule compound K279-0671, and the changes in liver metastases were detected before treatment, during treatment (10th day), and at the end of treatment (20th day). The results showed that the intraperitoneal injection concentrations of 25 mg / kg and 50 mg / kg could effectively inhibit the progression of liver metastasis and achieve the effect of alleviating the disease on the 20th day. Patient-derived breast cancer, colorectal cancer, and non-small cell lung cancer liver metastasis tumor organoid models and patient-derived breast cancer and colorectal cancer liver metastasis tumor xenograft tumor models were constructed, and K279-0671 was used as a single drug for treatment experiments. The results showed that K279-0671 can effectively inhibit the growth of liver metastasis tumor organoids and xenograft tumors. It can be seen that the small molecule compound K279-0671 targeting ppMAKL has good clinical application prospects and transformation value for the treatment of solid tumor liver metastasis. The present invention clarifies the molecular mechanism of solid tumor liver metastasis, screens and identifies effective biological targets, and has important clinical significance for the development of new targeted drugs and the improvement of the treatment effect and survival prognosis of liver metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0022] Figure 1 This is the Sanger sequencing result;

[0023] Figure 2CircMASTL-M is selectively highly expressed in breast cancer liver metastasis and mediates resistance to oxidative stress, where A is the fluorescence in situ hybridization experiment to detect the expression level of CircMASTL-M gene in different tumor cell lines; B is the in situ hybridization experiment to detect the expression level of CircMASTL-M gene in primary breast cancer tumors and liver metastasis tissues; CE is the targeted metabolic mass spectrometry to detect the abundance changes of folate-methionine cycle and redox metabolites; F is the flow cytometry experiment to detect lipid peroxidation; G is the flow cytometry experiment to detect the changes in cell death;

[0024] Figure 3 circMASTL-M encodes a new kinase-like polypeptide - ppMAKL, and can promote the occurrence of liver metastasis, where A is the vector for constructing the polypeptide encoded by circMASTL-M in vivo; B is Western blotting to prove that the wild-type circMASTL-M gene can encode the polypeptide ppMAKL (420aa); C is the dual luciferase reporter system detection to prove that the ribosome entry sites (IREs) on the circMASTL-M gene drive the encoding of ppMAKL; D is Aphafold predicts that ppMAKL has kinase domain; E is an in vitro kinase experiment proving that ppMAKL (420aa) has classical PKC kinase activity; F is an in vitro kinase experiment to detect the change in kinase activity after mutating the conservative amino acids in the ppMAKL kinase domain, **p<0.01, ***p<0.001; G is the construction of ppMAKL-specific antibodies, and immunohistochemical detection of the expression level of ppMAKL in different solid tumor primary lesions and different visceral metastases; H is the in vivo imaging of small animals to detect liver metastasis in MMTV-PYMT mice after injection of AAV virus;

[0025] Figure 4The small molecule compound targeting ppMAKL has a significant therapeutic effect on liver metastasis of solid tumors in various animal models; A is the computer simulation and molecular docking experimental process; B is the chemical structure of the small molecule compound K279-0671 that specifically targets ppMAKL; C is computer simulation and molecular docking showing that the small molecule compound K279-0671 can bind to the active cavity of ppMAKL; D is the plasma surface resonance experiment (SPR) showing that the affinity constant of the small molecule compound K279-0671 and ppMAKL is 2.49μM; E is that the small molecule compound K279-0671 can significantly enhance the stability of liver metastasis breast cancer cells Sensitivity to oxidative stress; F is that the small molecule compound K279-0671 can significantly enhance the sensitivity of colorectal cancer cells with stable liver metastasis to oxidative stress; G is that the small molecule compound K279-0671 can significantly enhance the sensitivity of non-small cell lung cancer cells with stable liver metastasis to oxidative stress; H is that in animal models of liver metastasis of various solid tumors, different concentrations of the small molecule compound K279-0671 have the therapeutic effect of inhibiting liver metastasis; IK is the statistical analysis of the inhibitory effect of different concentrations of the small molecule compound K279-0671 on liver metastasis, the blue line is the Placebo group, the green line is the 25mg / kg group, and the red line is the 50mg / kg group;

[0026] Figure 5 These are the experimental results of tumor inhibition in patient-derived organoids and patient-derived xenograft tumor mouse models; AC are the inhibitory effects of K279-0671 on breast cancer liver metastasis tumor organoids, colorectal cancer liver metastasis tumor organoids, and non-small cell lung cancer liver metastasis tumor organoids, respectively; DG is the inhibitory effect of K279-0671 on breast cancer liver metastasis tumors and colorectal cancer liver metastasis tumors in patient-derived xenograft tumor mouse models; C30 is K279-0671, and Placebo is placebo (PBS). DETAILED DESCRIPTION

[0027] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0028] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0029] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0030] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0031] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0032] Unless otherwise specified, the cells and preparations used in the examples are all purchased routinely by those skilled in the art.

[0033] Example 1

[0034] The full length of human hsa_circ_0018038 is 1260 nt (SEQ ID NO.1, specifically GAAAGTGATGAAGCATTGGGCCCAACAATGATGAGTTGGAATGCAGTTGAAAAGTTATGCGCAAAATCTGCAAATGCCATTGAGACGAAAGGTTTCAATAAAAAGGATCTGGAGTTAGCTCTTTCTCCCATTCATAACAGCAGTGCCCTTCCCACCACTGGACGCTCTTGTGTAAACCTTGCTAAAAAATGCTTCTCTGGGGAAGTTTCTTGGGAAGCAGTAGAACTGGATGTAAATAATATAAATATGGACACTGACACAAGTCAGTTAGGTTTCCATCAGTCAAATCAGTGGGCTGTGGATTCTGGTGGGATATCTGAAGAGCACCTTGGGAAAAGAAGTTTAAAAAGAAATTTTGAGTTGGTTGACTCCAGTCCTTGTAAAAAAATTATACAGAATAAAAAAACTTGTGTAGAGTATAAGCATAACGAAATGACAAATTGTTATACAAATCAAAATACAGGCTTAACAGTTGAAGTGCAGGACCTTAAGCTATCAGTGCACAAAAGTCAACAAAATGACTGTGCTAATAAGGAGAACATTGTCAATTCTTTTACTGATAAACAACAAACACCAGAAAAATTACCTATACCA), with 1 open reading frame, but its specific biological function is unclear. Human hsa_circ_0018038 is formed by reverse splicing of the 1st and 2nd exons of the linear gene MASTL. By designing "back-to-back" primers (has_circ_0018038-F1:TTACTAGGCAGGGCCCATGG, SEQ ID NO.2; has_circ_0018038-R1:GGAAGGGCACTGCTGTTATGA, SEQ ID NO.3) and combining Sanger sequencing, the reverse-cut circular adapter sequence (SEQ ID NO.4, specifically: TAGGCAGGGCCCATGG) can be obtained. GG AAAGTGATGAAGCAT, the bold italic underlined part is the circularization site) was amplified. The Sanger sequencing results are as follows Figure 1 As shown, it was confirmed that the hsa_circ_0018038-specific circularization adapter sequence was formed by reverse splicing of the 1st and 2nd exons of the linear gene MASTL.

[0035] Subsequently, hsa_circ_0018038 was named circMASTL-Metastase (circMASTL-M for short).

[0036] circMASTL-M has an open reading frame and is predicted to encode a polypeptide with 420 amino acids (SEQ ID NO.5, MMSWNAVEKLCAKSANAIETKGFNKKDLELALSPIHNSSALPTTGRSCVNLAK KCFSGEVSWEAVELDVNNINMDTDTSQLGFHQSNQWAVDSGGISEEHLGKRSLKRNFELVDSSPCKKIIQNKKTCVEYKHNEMTNCYTNQNTGLTVEVQDLKLSVHKSQQNDCANKENIVNSFTDKQQTPEKLPIPMIAKNLMCELDEDCEKNSKRDYLSSSFLCSDDDRASKNISMNSDSSFPGISIMESPLESQ PLDSDRSIKESSFEESNIEDPLIVTPDCQEKTSPKGVENPAVQESNQKMLGPPLEVLKTLASKRNAVAFRSFNSHINASNNSEPSRMNMTSLDAMDISCAYSGSYPMAITPTQKRRSCMPHQQTPNQIKSGTPYRTPKSVRRGVAPVDDGRILGTPDYLAPELLLGRAHGK), named it ppMAKL (polypeptide Metastases Associated Kinase-Like).

[0037] Example 2

[0038] (1) Fluorescence in situ hybridization (FISH)

[0039] In this example, the RiboTM fluorescence in situ hybridization kit (Ribo Bio, Cat. C10910) was used, and the experimental process strictly followed the product instructions. The experimental process is briefly summarized as follows: Different tumor cell lines are inoculated into a special dish for confocal microscope in advance, and they can be used for experiments when the degree of fusion reaches 60%. After washing once with PBS, the cells are fixed with 4% paraformaldehyde for 10 minutes and treated with permeabilization solution for 5 minutes. The pre-hybridization solution was blocked at 37°C for 30 minutes, the probe was diluted to 0.5μM with the hybridization solution, and incubated overnight at 37°C. The hybridization solution was discarded the next day, and the unhybridized probes were washed away with hybridization wash solution in turn. Incubate the cell nucleus with DAPI staining solution to stain it. After washing, add antifade agent dropwise, store at 4°C in the dark, and observe under a confocal microscope.

[0040] (2) In situ hybridization experiment

[0041] In this example, RNA in situ hybridization uses Boster Sensitivity Enhanced In Situ Hybridization Detection Kit I, and the experimental process follows the product instructions. The pepsin digestion time is 10 minutes at room temperature, and the probe uses a digoxin-labeled specific probe targeting the circMASTL-M gene junction sequence (specifically UUCAUCACUU (SEQ ID NO.6) + UCCAUGGGCCC (SEQ ID NO.7)). The hybridization conditions are 0.5 μg / mL, 40°C. The rest of the routine steps are the same as immunohistochemical staining. The tissue samples used in the experiment were derived from the biological sample bank of Shantou Central Hospital (National Science and Technology Heritage Office Review No. "2022" BC008).

[0042] (3) Targeted metabolomics

[0043] MDA-MB-231 and 231LM cells were 13 After C labeling, the metabolites were fixed and extracted with a methanol-acetonitrile mixed solvent, and the changes in the abundance of related metabolites were detected by high-resolution liquid chromatography-mass spectrometry.

[0044] (4) Lipid peroxidation detection

[0045] Divided into 2 treatment groups, namely PBS group (control group) and TBH group (tert-butyl hydroperoxide treatment group), each group has 4 treatment methods. First, MDA-MB-231 was transfected with overexpression vector plasmids (Vec, ATG, circMASTL-M, 420aa): 8 hours before transfection, MDA-MB-231 cells were inoculated in 6-well cell culture plates to make the cell fusion degree about 60% after attachment; Lipo3000 transfection reagent (Thermo) was used to prepare plasmid transfection mixture according to the instruction manual, and it was left to stand for 15 minutes until the plasmid and transfection reagent were completely fused and then added to the cell culture medium. After 24 hours, fresh culture medium was replaced, 500uL PBS solution was added to the PBS group, and 100uM TBH was added to the TBH group, and culture was continued for 24 hours.

[0046] The cells of each group were digested and centrifuged to precipitate the cells. Then, BODIPY 581 / 591C11 (lipid peroxidation sensor, Thermo) probe was added and incubated at 37°C for 30 minutes. The lipid peroxidation ratio was detected by flow cytometry for quantitative analysis.

[0047] (5) Cell death experiment

[0048] Divided into 2 treatment groups, namely PBS group (control group) and TBH group (tert-butyl hydroperoxide treatment group), each group has 4 treatment methods. First, MDA-MB-231 was transfected with overexpression vector plasmids (Vec, ATG, circMASTL-M, 420aa): 8 hours before transfection, MDA-MB-231 cells were inoculated in 6-well cell culture plates to make the cell fusion degree about 60% after attachment; Lipo3000 transfection reagent (Thermo) was used to prepare plasmid transfection mixture according to the instruction manual, and it was left to stand for 15 minutes until the plasmid and transfection reagent were completely fused and then added to the cell culture medium. After 24 hours, fresh culture medium was replaced, 500uL PBS solution was added to the PBS group, and 100uM TBH was added to the TBH group, and culture was continued for 24 hours. The cells in each group were digested and centrifuged to precipitate the cells. Live / dead cell staining (calcein / PI staining method) was performed on the cells in each treatment group. The changes in the live / dead cell ratio in each group were detected by flow cytometry.

[0049] (6) Results

[0050] Fluorescence in situ hybridization experiments showed that the expression level of circMASTL-M gene was significantly increased in breast cancer cells with stable liver metastasis (231LM and MCF-7LM) and colorectal cancer cells with stable liver metastasis (KM12-SM and 116LM). Figure 2A in Figure 3); In situ hybridization experiments showed that the expression level of circMASTL-M gene in liver metastasis tissues of both breast cancer and colorectal cancer was significantly increased compared with that in primary tumor tissues ( Figure 2 B); Targeted metabolomics results showed that after knocking down the circMASTL-M gene in breast cancer cells with stable liver metastasis (circMASTL si), the folate-methionine cycle in breast cancer cells was inhibited, and reduced metabolites such as glutathionine (GSH) and NADPH were significantly reduced, while oxidized metabolites such as GSSG and NADP + It significantly increased ( Figure 2 CE in the experiment); the results of lipid peroxidation detection and cell death experiments showed that after overexpression of circMASTL-M gene in non-metastatic breast cancer cells, the resistance of tumor cells to oxidative stress was significantly increased, which was manifested by reduced lipid peroxidation level and reduced breast cancer cell death ( Figure 2 FG in ).

[0051] Example 3

[0052] (1) Construction of a wild-type vector of the circMASTL-M gene that forms a circle in vivo and translates a polypeptide and a mutant vector with a mutated translation start codon ATG (ΔATG)

[0053] All wild-type and mutant vectors were constructed by Guangzhou Jisai Biotechnology Co., Ltd., and the vector skeleton structure patent used is owned by Guangzhou Jisai Co., Ltd. First, MDA-MB-231 was transfected with overexpression vector plasmids (Vec, ΔATG, circMASTL-M, 420aa): 8 hours before transfection, MDA-MB-231 cells were inoculated in a 6-well cell culture plate, so that the fusion degree of cells after attachment was about 60%; Lipo3000 transfection reagent (Thermo) was used to prepare plasmid transfection mixture according to the instruction manual, and it was left to stand for 15 minutes until the plasmid and transfection reagent were completely fused, and then added to the cell culture medium. After 24 hours, fresh culture medium was replaced and cultured for another 24 hours. Cell lysate was used to extract cell proteins in each group, and western blotting experiments were performed.

[0054] (2) Dual luciferase reporter assay

[0055] The wild-type luciferase reporter vector carrying the full-length ribosome entry site on circMASTL-M and the luciferase reporter vector containing the truncated ribosome entry site were transfected into 293T cells using Lipo3000 transfection reagent, respectively. After 48 hours, the cells were lysed and reacted according to the instructions of the Promega dual-luciferase reporter assay kit, and the fluorescence value was detected using a Biotech multi-function microplate reader.

[0056] (3) Aphafold predicts that ppMAKL has a kinase domain

[0057] The structure of the peptide was analyzed using AphaFold software.

[0058] (4) In vitro kinase assay

[0059] Prepare kinase reaction solution: 25mM Tris (pH 7.5), 2mM DTT, 10mM MgCl2. Prepare 5× stock solution and save for later use. Before use, add 2.5μL 20× protease inhibitor, 2.5μL 20× phosphatase inhibitor and ATP to 45μL kinase reaction solution, with a final ATP concentration of 200μM, to obtain 50μL kinase reaction mixed solution.

[0060] Use 50 μL of kinase reaction mixture to dissolve 10 μg of substrate protein or kinase (manufacturer: abcam, catalog number: ab139437), where the substrate protein is ppMAKL (420aa, WT) or ppMAKL mutants (ppMAKL mutants are Mut1, Mut2 and Mut3), react at 30°C for 50 min, terminate the reaction in a boiling water bath for 10 min, and perform detection, or quick-freeze in liquid nitrogen, store for a long time at -80°C, or perform subsequent experiments.

[0061] (5) Immunohistochemistry experiment

[0062] A specific polyclonal antibody (prepared by Nanjing GenScript Biotech Co., Ltd.) was constructed for the antigenic epitope of ppMAKL. The specific antibody was used to verify the expression of ppMAKL in various metastatic tissues of solid tumors through immunohistochemistry experiments. The specific steps are as follows:

[0063] ① Dewaxing and hydration: the steps are the same as HE staining.

[0064] ② Antigen repair: After washing once with PBS, immerse the tissue in 1×EDTA repair solution and cover the lid to reduce evaporation. After boiling water in the pressure cooker, put the cylinder containing the slices in it. When the pressure cooker starts to steam, start timing for 2.5 minutes. After natural cooling, open the lid and take out the cylinder. After cooling to room temperature, proceed to the next step.

[0065] ③ Block endogenous peroxide: After washing once with PBS, immerse the tissue in 3% hydrogen peroxide for 10 minutes.

[0066] ④ Blocking: Wash three times with PBS, wipe off excess water on the slide, use an immunohistochemistry pen to draw a closed hydrophobic circle around the tissue, add 20% goat serum on the tissue, and block at room temperature for 30 minutes.

[0067] ⑤ Primary antibody incubation: Dilute the Ki67 antibody at 1:2000. After removing the excess blocking solution, add the primary antibody dilution solution directly and incubate in a humidified box at 4°C overnight.

[0068] ⑥ Secondary antibody incubation: After removing the primary antibody reagent, wash with PBS three times. Add the secondary antibody for immunohistochemistry (manufacturer: Zhongshan Jinqiao, catalog number: PV-6000) and incubate at room temperature for 30 minutes.

[0069] ⑦DAB color development: After removing the secondary antibody reagent, wash three times with PBS. Prepare DAB color development solution, shake off excess water and drip the color development solution on the tissue, observe the staining depth under a microscope, and take the longest time without non-specific staining as the standard, and place the slice in distilled water to dilute the color development solution to terminate the reaction.

[0070] ⑧Hematoxylin staining, differentiation and blueing: the steps are the same as HE staining.

[0071] ⑨ Dehydration, transparentization and sealing: the steps are the same as HE staining.

[0072] ⑩ Scoring and statistics: Analysis and scoring were performed using ImageJ software.

[0073] (4) Small animal in vivo imaging experiments

[0074] A liver metastasis model was constructed by injecting tumor cells labeled with fluorescent dye into the spleen of mice. Then, adenovirus loaded with ppMAKL or empty adenovirus was injected into the mammary tumor of MMTV-PYMT mice that spontaneously formed mammary tumors, and then in vivo imaging detection was performed.

[0075] Before in vivo imaging, 100 μL of D-luciferin was injected into the abdominal cavity. After 10 minutes, the mice were anesthetized and placed in the in vivo imaging detection chamber. The fluorescence distribution was captured and analyzed using IVIS Lumina.

[0076] (5) Results

[0077] Western blotting experiments confirmed that the circMASTL-M gene can encode ppMAKL ( Figure 3 A and B in Figure 3); Dual luciferase reporter assay confirmed that circMASTL-M gene is driven by IREs to translate ppMAKL ( Figure 3 C in the figure); The structure of the peptide was analyzed using AphaFold software, and it was found that ppMAKL has the activation domain of the classic PKC kinase ( Figure 3 D in the figure); in vitro kinase assay confirmed that ppMAKL has kinase activity ( Figure 3E and F in Figure 1). A specific polyclonal antibody was constructed against the antigenic epitope of ppMAKL. Immunohistochemical experiments using this specific antibody confirmed that ppMAKL was highly expressed in various metastatic tissues of solid tumors, including bone metastasis, lymph node metastasis, lung metastasis and liver metastasis, especially in liver metastasis. The expression was significantly increased ( Figure 3 G in the figure); After the adenovirus (AAV) loaded with ppMAKL and the empty adenovirus were injected into the breast tumor of MMTV-PYMT mice that spontaneously developed breast tumors, it was found through in vivo imaging that ppMAKL infection of the primary tumor promoted the metastasis of tumor cells to the liver ( Figure 3 H in.

[0078] Example 4

[0079] (1) Computer simulation and molecular docking screening of compounds

[0080] a. Method for constructing a screening platform: In virtual drug screening, the five principles of drug-likeness are often used as one of the important screening rules. Compounds that meet this rule will have better pharmacokinetic properties, such as good membrane permeability and bioavailability. First, the drug library containing 1.4 billion small molecules was screened according to the five principles of drug-likeness. The specific rules are shown in Table 1.

[0081] Table 1 Rules

[0082]

[0083] The candidate small molecules were screened by the above rules, and these small molecules will be used for subsequent docking-based virtual screening. Gasteiger charges were added to the small molecules that passed the five principles of drug-likeness for AutoDockVina docking. The docking operation is to place each small molecule in the ligand binding site of the receptor protein, adjust the ligand conformation and position, calculate the docking score of each ligand conformation, and select the conformation with the best score as the final selected conformation. The top 5000 small molecules in the docking score will be selected as the molecules for the subsequent screening scheme. The top 5000 small molecules are further clustered and analyzed by chemical type, and the top 500 small molecules are selected for further screening. The top 500 small molecules are manually screened to remove small molecules that exceed the set active cavity size and small molecules that do not have hydrogen bonding forces, and select the top 43 small molecule compounds. Later, in vitro kinase experiments and plasma surface resonance experiments determined that K279-0671 has a strong affinity with ppMAKL and can inhibit its kinase activity.

[0084] (2) Plasmon surface resonance experiment

[0085] Install the NTA chip according to the OpenSPRTM instrument standard operating procedure, adjust the flow rate with buffer, activate the chip, take out the prepared imidazole and NiCI2 solutions, and prepare the ligand through the injection port. Observe the baseline for 5 minutes to ensure stability. Measure the amount of ligand binding by comparing the signal before and after injection of the ligand. After the ligand signal stabilizes, start injecting high concentrations of analyte to confirm the activity of the ligand and confirm the approximate maximum binding capacity of the surface. Increase the flow rate to 150μL / min and inject appropriate regeneration buffer to remove the analyte. Pharmacokinetics and affinity parameters were analyzed using TraceDrawer (Ridgeview Instruments ab, Sweden) software.

[0086] (3) Preparation of small molecule compound K279-0671

[0087] The small molecule compound K279-0671 was synthesized by Chemicaldiv, and the patent for the compound synthesis pathway is owned by Chemicaldiv.

[0088] (4) Compound IC 50 Detection experiment

[0089] They were divided into three groups: PBS+K279-0671 group, TBH+K279-0671 group and TBH+K279-0671+LIP-1 group.

[0090] Specifically, the PBS+K279-0671 group was as follows: 231LM, KM12-SM, and A549LM cells were inoculated into 96-well cell culture plates, respectively, and K279-0671 was added to the culture medium at a concentration gradient (0, 0.1, 0.5, 1, 5, 10, 30, 60, and 100 μM) and cultured for 24 hours, and then PBS was added to continue culturing for 24 hours, and the cell viability / toxicity detection reagent (MTS kit, promega) was added for incubation 2 hours before the test;

[0091] TBH+K279-0671 group: 231LM, KM12-SM, and A549LM cells were seeded in 96-well cell culture plates, respectively. K279-0671 was added to the culture medium at a concentration gradient (0, 0.1, 0.5, 1, 5, 10, 30, 60, and 100 μM) and cultured for 24 hours. Then, 100 μM TBH was added and cultured for another 24 hours. Cell viability / toxicity detection reagent (MTS kit, Promega) was added for incubation 2 hours before detection.

[0092] In the TBH+K279-0671+LIP-1 group, 231LM, KM12-SM, and A549LM cells were seeded into 96-well cell culture plates, respectively. K279-0671 was added to the culture medium at a concentration gradient (0, 0.1, 0.5, 1, 5, 10, 30, 60, and 100 μM) and cultured for 24 hours. Then, 100 μM TBH and 1 μM Liproxstatin-1 (Selleck, Cat. S7699) were added and cultured for another 24 hours. Cell viability / toxicity detection reagent (MTS kit, promega) was added for incubation 2 hours before detection.

[0093] Afterwards, the chemiluminescence (OD value) of each group was detected by a multifunctional microplate reader, and the proliferation inhibition rate was calculated as [(OD value of the control group - OD value of the experimental group) / OD value of the control group] × 100% to obtain the proliferation inhibition rate corresponding to each drug concentration. The IC value of small molecule compounds was calculated using SPSS and Gradpadprism 9.0 software 50 .

[0094] (7) Small animal liver metastasis treatment model

[0095] Take 1×10 tumor cells (MDA-MB-231 cells, HCT116 cells or A549 cells) in the logarithmic growth phase and labeled with fluorescence. 6 90 BALB / c nude mice were anesthetized, the skin of the surgical field was disinfected, and an oblique incision of about 1 cm was made on the left upper abdomen of the nude mice. The spleen was gently pulled out of the abdominal cavity with tissue forceps to a gauze moistened with saline. The tumor cells were slowly injected into the spleen of the corresponding nude mice with an insulin syringe. Each nude mouse was injected with 50 μL of cell suspension. The spleen capsule was swollen and whitened. Pay attention to keep the spleen moist during injection. After the injection of each group, 75% (volume percentage) alcohol cotton balls were used to press the needle eye for 10 minutes to stop bleeding and kill cancer cells that may extravasate, prevent and treat intraperitoneal implantation and metastasis, and then the spleen was gently returned to its original position and the wound was sutured to obtain a mouse model of liver metastasis of non-small cell lung cancer, a mouse model of liver metastasis of colorectal cancer, and a mouse model of liver metastasis of breast cancer. The liver metastasis was observed by small animal live imaging every week. After the liver metastasis appeared, each type of mouse model was divided into 3 groups on average, namely Placebo group, 25mg / kg group and 50mg / kg group.

[0096] The specific steps of the Placebo group were as follows: 100uL of sterile saline was injected intraperitoneally every 2 days for a total of 10 injections;

[0097] The specific steps of the 25 mg / kg group were as follows: treatment was performed by intraperitoneal injection of 25 mg / kg of K279-0671, once every 2 days, for a total of 10 injections;

[0098] The specific steps of the 50 mg / kg group were as follows: treatment was carried out by intraperitoneal injection of 50 mg / kg of K279-0671, once every 2 days, for a total of 10 injections.

[0099] (8) Results

[0100] Targeting the active cavity of ppMAKL, a small molecule compound K279-0671 ( Figure 4 Surface plasmon resonance (SPR) technology confirmed that the small molecule compound has a good affinity with ppMAKL ( Figure 4 D). Cell proliferation experiments showed that K279-0671 could increase the sensitivity of breast cancer cells with stable liver metastasis (231LM), colorectal cancer cells with stable liver metastasis (KM12-SM), and non-small cell lung cancer cells with stable liver metastasis (A549LM) to oxidative stress, which was manifested by enhanced sensitivity to TBH, IC 50 When the lipid peroxidation inhibitor Lip-1 was added for rescue, the sensitivity of tumor cells to TBH decreased significantly, and IC 50 Rebound Figure 4 EG in).

[0101] By constructing an animal model of liver metastasis of solid tumors (Cell-Derived Xengraft, CDX) with common liver metastases in clinical practice, including breast cancer, colorectal cancer, non-small cell lung cancer, etc., a treatment experiment was conducted with a small molecule compound K279-0671 at different concentrations. The changes in liver metastases were detected before treatment, during treatment (10th day), and at the end of treatment (20th day). The results showed that intraperitoneal injection concentrations of 25 mg / kg and 50 mg / kg could effectively inhibit the progression of liver metastasis and achieve disease remission (lesion disappearance) on the 20th day ( Figure 4 Therefore, the small molecule compound K279-0671 targeting ppMAKL has good clinical application prospects and translational value in the treatment of solid tumor liver metastasis.

[0102] Example 5

[0103] 1. Organoid establishment, culture and drug sensitivity testing methodology

[0104] Freshly isolated breast cancer liver metastasis tissue blocks, colorectal cancer liver metastasis tissue blocks, and ovarian cancer liver metastasis tissue blocks were collected, rinsed with sterile PBS, rinsed twice with 10 mL of AdDF+++ medium (advanced DMEM / F12 containing 1× glutamine, 10 mM HEPES, and antibiotics), and minced into 1-2 mm small pieces.

[0105] 10 mL of dissociation medium (based on F12 and DMEM (the volume ratio of F12 and DMEM is 1:1), to which 2% (w / v) bovine serum albumin, 300 U / mL collagenase, 100 U / mL hyaluronidase, 10 ng / mL epidermal growth factor (EGF), 1 mg / mL insulin, and 0.5 mg / mL hydrocortisone are added) is added to the tumor fragments and kept at 37°C with constant shaking at 275 rpm for 2 hours. The separated tumor fragments are centrifuged at 1200 rpm for 5 minutes, and if the cell pellet is obviously red, red blood cell lysis is performed according to the manufacturer's protocol (BD Biosciences). 3 mL of preheated trypsin is added and incubated in a bead bath at 37°C for 5-7 minutes to further separate the tumor fragments. 6 mL of neutralization solution (PBS containing 2% FBS) is added and centrifuged at 1200 rpm for 5 minutes. The tumor microspheres were then treated with a disase / DNAse mixture for 5-7 minutes at 37°C, neutralized and centrifuged. The tumor cell suspension was treated using the EasySep Human Biotin Positive Selection Kit II (STEMCELL, #17663). The cell pellet was resuspended in an appropriate volume of cold BME, 40 mL of cell suspension was added to the center of each well of a 24-well plate, allowed to solidify, and incubated at 37°C for 20 minutes.

[0106] Add 500 mL of organoid culture medium (based on F12 and DMEM, supplemented with 250 ng / mL R-Spondin3, 5 nM Neuregulin1, 5 ng / mL FGF7, 20 ng / mL FGF10, 5 ng / mL EGF, 100 ng / mL Noggin, 500 nM A83-01, 5 μM Y-27632, 500 nM SB202190, 1×B27 supplement, 1.25 mM N-Acetylcysteine, 5 mM Nicotinamide, 1×GlutaMax, 10 mM Hepes, 50 μg / mL primocin, 100 U / mL penicillin and 100 μg / mL streptomycin) to each cell culture dish, inoculate the incubated cells, and then return to the incubator at 37°C and a CO2 level of 2% for culture to obtain organoids.

[0107] For viability assays, established organoids were isolated into single cell suspensions by mechanical shearing and enzymatic cleavage using TrypLE express (Gibco, #12604021). Isolated cells were resuspended in 100 mL of cold organoid medium containing 5% BME and seeded at a density of 1000 cells / well in 96-well plates coated with BME in organoid medium without EGF and NRG1. The next day, organoid cultures were treated with different concentrations of K279-0671 (64.000, 32.000, 16.000, 8.000, 4.000, 2.000, 1.000, 0.500 and 0.250 μM), and cell viability was assessed using the CellTiter-Glo 3D Viability Assay Kit (Promega #G9681) after 6 days of observation. Organoids were photographed with a Leica DMi1 inverted microscope.

[0108] 2. Construction of Patient Derived Xengraft (PDX) Model and Drug Treatment Trial

[0109] Fresh breast cancer liver metastasis tumor tissue (BCM1395) and colorectal cancer liver metastasis tumor tissue (CCM0847) were collected and placed in a sterile dish filled with physiological saline. The connective tissue and blood vessels on the surface of the tumor tissue were removed with sterile instruments. The tumor was cut open along the midline to remove necrotic tissue, calcium spots and secretions. Tumor tissue with good quality was selected and cut into 2*2*2mm 3 The tumor mass is kept aside.

[0110] The prepared tumors were inoculated subcutaneously on the right back of 30 B-NDG mice. When the average tumor volume reached 200-300 mm 3 At 14:00, 20 mice were selected according to tumor volume and body weight and randomly assigned to 2 experimental groups, 10 mice in each group. Drug administration began on the day of grouping (Day 0). The specific drug administration schedule is shown in Table 2.

[0111] Table 2 Dosage regimen

[0112]

[0113] Note: ip means intraperitoneal injection, Q2D means once every two days, the same as in the following table.

[0114] After grouping, the tumor volume was measured twice a week using a vernier caliper. The tumor volume was measured before euthanasia. The long diameter and short diameter of the tumor were measured. The volume calculation formula was: tumor volume = 0.5 × long diameter × short diameter 2 When mice died midway or were euthanized early, or at the end of the experiment, the mouse tumors were removed and weighed, and the euthanized animals and tumors were photographed and recorded.

[0115] 3. Experimental results

[0116] After the organoid models of breast cancer liver metastasis tumor tissue, colorectal cancer liver metastasis tumor tissue, and non-small cell lung cancer liver metastasis tumor tissue were successfully constructed, different concentrations of K279-0671 were added for culture, and the culture medium and drugs were replaced by half every 48 hours. After 6 days of total culture, the changes in cell viability were detected. The results showed that K279-0671 had a significant inhibitory effect on breast cancer liver metastasis tumor organoids, IC 50 5.20uM( Figure 5 A); it also has a good inhibitory effect on colorectal cancer liver metastasis tumor organoids and non-small cell lung cancer liver metastasis tumor organoids, IC 50 They are 14.08uM and 3.047uM respectively ( Figure 5 B and C in the figure). At the same time, human breast cancer liver metastasis tumor tissue and human colorectal cancer liver metastasis tumor tissue xenograft tumor models were constructed and treated with K279-0671. The results showed that K279-0671 also had a good inhibitory effect on breast cancer liver metastasis tumors and colorectal cancer liver metastasis tumors in PDX models ( Figure 5 DG in ).

[0117] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. Application of ppMAKL as a target in screening drugs for treating liver metastasis of solid tumors, characterized in that: The amino acid sequence of ppMAKL is shown in SEQ ID NO.

5.

2. The use according to claim 1, characterized in that: The solid tumors include breast cancer, colorectal cancer and non-small cell lung cancer.

3. Use of a preparation for inhibiting the activity of ppMAKL in the preparation of a drug for treating liver metastasis of solid tumors, characterized in that: The amino acid sequence of ppMAKL is shown in SEQ ID NO.

5.

4. The use according to claim 3, characterized in that: The drug achieves the purpose of treating liver metastasis of solid tumors by increasing oxidative stress-induced ferroptosis of metastatic tumor cells and inhibiting the formation of liver metastasis.

5. The use according to claim 1, characterized in that: The solid tumors include breast cancer, colorectal cancer and non-small cell lung cancer.

6. Use of the small molecule compound K279-0671 in the preparation of a drug for treating liver metastasis of solid tumors, characterized in that: The chemical structure of the small molecule compound K279-0671 is shown in Formula I, 7. The use according to claim 6, characterized in that: The drug achieves the purpose of treating liver metastasis of solid tumors by inhibiting the metastasis of cancer cells to the liver.

8. A drug for treating liver metastasis of solid tumors, characterized in that: The active ingredient of the drug includes a small molecule compound K279-0671, and the chemical structure of the small molecule compound K279-0671 is shown in Formula I.

9. The drug according to claim 8, characterized in that The medicine also includes pharmaceutically acceptable excipients.

10. The drug according to claim 8, characterized in that The dosage form of the medicine is injection, granule, powder or capsule.